To the Editor: Kisker and Burke (N.E.J.M. 282:639–642, 1970) advocate the use of oral corticosteroids on a short-term basis in the treatment of the hemarthrosis of hemophilia. We are concerned about two aspects of their study. The first is the fact that they based their decision on the amount of blood-fraction replacement therapy required by the patient on their clinical evaluation of the affected joint. Decrease in pain and increase in motion in the patients treated with corticosteroids was equated with reduction of bleeding into the joint, an assumption that requires proof. In our experience, particularly with recurrent hemarthrosis, small.
ASJC Scopus subject areas